ConductScience.org, home

Comparison · NCT01706198-dc8695a6

FF/VI vs Usual Care: Number of Participants With Adverse Drug Reactions (ADRs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. FF/VI vs Usual Care: Number of Participants With Adverse Drug Reactions (ADRs). Trial comparisons, record NCT01706198-dc8695a6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01706198-dc8695a6

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1540.1390.17wilson
Risk in group 20.05140.04280.0617wilson
Risk difference, group 1 minus group 20.1030.08480.121newcombe hybrid score
Risk ratio, group 1 over group 232.433.69log
Odds ratio, group 1 over group 23.362.684.21log
Number needed to treat, for one more participant with the outcome on FF/VI than on Usual Care9.738.2711.8from the risk difference interval

Groups2

Group 2 names the comparator: usual care.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1FF/VIParticipants initiated with an appropriate dose of inhaled FF/VI (100 mcg/25 mcg or 200 mcg/25 mcg per actuation) once daily via Novel Dry Powder Inhaler.3262,114OG001
Group 2Usual Care
Participants continued their usual asthma maintenance therapy that is, inhaled corticosteroid without a long acting beta2-agonist or inhaled corticosteroid with long acting beta2-agonist combination (either as a fixed dose combination or an inhaled corticosteroid/long acting beta2-agonist provided in two separate inhalers).
1092,119OG000

Outcome

Type
SECONDARY
Title
Number of Participants With Adverse Drug Reactions (ADRs)
Description
An ADR is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. ADRs are a subset of AEs for a given medicinal product.
Time frame
Up to Week 52
Population
ITT Population

Source ClinicalTrials.gov

Trial

Title
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
NCT number
NCT01706198
Phases
PHASE3
Conditions
Asthma
Interventions
fluticasone furoate + vilanterol, inhaled corticosteroid with or without a long acting beta2-agonist
Lead sponsor
GlaxoSmithKline
Results first posted
2019-01-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01706198-dc8695a6